88 results match your criteria: "European Monitoring Centre for Drugs and Drug Addiction EMCDDA[Affiliation]"
Am J Public Health
January 2015
At the time of the study, Vana Sypsa, Dimitrios Paraskevis, Maria Kantzanou, Antigoni Katsoulidou, Mina Psichogiou, and Angelos Hatzakis were with the National Retrovirus Reference Center, Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, University of Athens, Greece. Meni Malliori and Anastasios Panopoulos were with the Organisation Against Drugs (OKANA), Athens. Georgios K. Nikolopoulos was with the Hellenic Center for Disease Control and Prevention, Athens. Anastasios Fotiou was with the Greek Reitox Focal Point of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), University Mental Health Research Institute, Athens. Anastasia Pharris and Marita Van De Laar were with the European Centre for Disease Prevention and Control, Stockholm, Sweden. Lucas Wiessing was with the EMCDDA, Lisbon, Portugal. Don Des Jarlais was with the Beth Israel Medical Center, New York, NY. Samuel R. Friedman was with the National Development and Research Institutes, New York, NY.
Objectives. We examined HIV prevalence and risk factors among injection drug users (IDUs) in Athens, Greece, during an HIV outbreak. Methods.
View Article and Find Full Text PDFPrev Sci
December 2014
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praca Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal,
Euro Surveill
November 2013
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
In most European Union (EU)/European Economic Area (EEA) countries, between 2010 and 2012, reports of new human immunodeficiency virus (HIV) diagnoses among people who inject drugs have been stable or declining. HIV outbreaks in Greece and Romania, first reported in 2011, continue and economic conditions hinder provision of effective response coverage. When measured against some established thresholds, prevention coverage remains inadequate in at least one-third of EU/EEA countries.
View Article and Find Full Text PDFBr J Clin Pharmacol
November 2013
Health Consequences, Prevalence, Consequences and Data Management Unit, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
ISRN Addict
May 2015
Prevalence and Consequences and Data Management Unit, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Cais do Sodré, 1249-289 Lisbon, Portugal.
The aim of this study was to examine the feasibility of problem cannabis use screening instruments administration within wide school surveys, their psychometric properties, overlaps, and relationships with other variables. Students from 7 Spanish regions, aged 14-18, who attended secondary schools were sampled by two-stage cluster sampling (net sample 14,589). Standardized, anonymous questionnaire including DSM-IV cannabis abuse criteria, Cannabis Abuse Screening Test (CAST), and Severity of Dependence Scale (SDS) was self-completed with paper and pencil in the selected classrooms.
View Article and Find Full Text PDFEpidemiol Infect
March 2013
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, The Netherlands.
Monitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged.
View Article and Find Full Text PDFJ Ethnopharmacol
December 2010
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Cais do Sodré, 1249-289 Lisbon, Portugal.
Aim Of The Study: To review the information available on the use of khat (Catha edulis) in the EU, and to assess the future use of this drug and related substances.
Material And Methods: Khat is not controlled by international law and it has not been systematically included in the list of illicit drugs monitored in the EU. The current principal source of information on khat use in Europe is the early-warning system set up to monitor new and emerging drugs.
Subst Use Misuse
February 2010
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
This article describes the findings of a descriptive analysis of 27 online drug retailers selling legal alternatives to illegal drugs, commonly referred to as "herbal highs" and "legal highs" in 2008 . The study attempted to quantify the online availability of drug retailers, to describe common products and characteristics in EU-based retail sales. The findings highlight the concern about the lack of objective information about products offered, including potential risks to health.
View Article and Find Full Text PDFDrug overdose is an important cause of death among young adults in Europe. According to data reported by Member States to the EMCDDA, many of the European Union countries reported a rebound in the numbers of overdose deaths in 2003-2005, following decreases in almost all reporting countries in previous years (2000 to 2003). Further investigations are needed in order to clarify the factor driving these increases and inform policies and interventions aimed at reducing these deaths.
View Article and Find Full Text PDFEuro Surveill
December 2008
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
The human immunodeficiency virus (HIV) epidemic among injecting drug users (IDUs) shows different developments in different parts of the European region. In the countries of the European Union (EU) and the European Free Trade Association (EFTA), the rates of reported newly diagnosed cases of HIV infection in IDUs are mostly at stable and low levels or in decline. In contrast, those rates increased in 2007 in many of the other (eastern) countries in the World Health Organization (WHO) European Region, suggesting that the HIV epidemic among IDUs in Europe is still growing.
View Article and Find Full Text PDF